Pharmaceutical

CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference

HOUSTON, TX / ACCESSWIRE / July 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…

11 months ago

In Honor of World Nature Conservation Day, Jaguar Health Announces Planting of More Than 1.1 Million Trees in Peruvian Amazon

Activities support sustainable supply of Jaguar's botanical drug crofelemer, the active ingredient in the company's FDA-approved human drug Mytesi® and…

11 months ago

Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings

ORLANDO, FL / ACCESSWIRE / July 27, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products,…

11 months ago

Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients

Scholarships Awarded to Six Students Affected by Dermatologic ConditionsLAVAL, QC / ACCESSWIRE / July 27, 2023 / Bausch Health Companies…

11 months ago

NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

FT. MYERS, FL / ACCESSWIRE / July 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced…

11 months ago

NABP Collaborates With IBM to Build New Digital Platform to Protect the Drug Supply Chain

Pulse by NABP™ to connect the full supply chain that provides safe medication to patients in the United States |…

11 months ago

Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization

CAMBRIDGE, Mass., and DEVENS, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing…

11 months ago

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)

WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,…

11 months ago

Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the…

11 months ago

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)

Topline data expected in 2024MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”),…

11 months ago